Patrick Crutcher

Nessuna posizione attualmente

39 anni

Consumer Services

Health Technology

Profilo

Patrick J.
Crutcher is currently the President & Chief Executive Officer at AlmataBio, Inc. Previously, he served as the Chairman & President at Ichorion Therapeutics, Inc. from 2017 to 2018.
He also worked as the Chief Strategy Officer at Avalo Therapeutics, Inc. in 2019.
Mr. Crutcher holds a graduate degree from the University of California, Los Angeles and an undergraduate degree from the University of Illinois.

Posizioni attive di Patrick Crutcher

Società	Posizione	Inizio

Tutte le posizioni attive di Patrick Crutcher

Precedenti posizioni note di Patrick Crutcher

Società	Posizione	Fine
AVALO THERAPEUTICS, INC.	Corporate Officer/Principal	01/11/2019
Ichorion Therapeutics, Inc. Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ichorion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of treatments for rare diseases. It focuses on a pipeline of genetically-targeted therapies for inherited metabolic disorders known as Inborn Errors of Metabolism. The company was founded by Stephen Thomas on July 7, 2017 and is headquartered in New York, NY.	Amministratore Delegato	01/09/2018

Vedi nel dettaglio l'esperienza di Patrick Crutcher

Formazione di Patrick Crutcher

University of California, Los Angeles	Graduate Degree
University of Illinois	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Patrick Crutcher

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
AVALO THERAPEUTICS, INC.	Health Technology

Aziende private	1
Ichorion Therapeutics, Inc. Ichorion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ichorion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of treatments for rare diseases. It focuses on a pipeline of genetically-targeted therapies for inherited metabolic disorders known as Inborn Errors of Metabolism. The company was founded by Stephen Thomas on July 7, 2017 and is headquartered in New York, NY.	Health Technology